We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clover Health Investments, Corp. (CLOV - Free Report) delivered a loss per share of 2 cents in the third quarter of 2024, narrower than the year-ago period’s loss of 7 cents per share and the Zacks Consensus Estimate of a loss of 3 cents per share.
CLOV’s Revenues in Detail
Clover Health registered revenues of $330.9 million in the third quarter, up 8.2% year over year. However, the figure missed the Zacks Consensus Estimate by 4.8%.
The top line was aided by robust Insurance revenues and Other income.
Shares of this company plunged nearly 12.7% in yesterday’s after-hours trading.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Clover Health’s Segmental Details
Clover Health derives its revenues from two business sources — Insurance and Other income.
Insurance revenues in the third quarter totaled $322.6 million, indicating an uptick of 7.1% year over year. Per management, this was primarily driven by strong member retention and continued intra-year growth.
Within CLOV’s Insurance segment, the Insurance Benefits Expense Ratio (BER) was 82.8% in the third quarter of 2024, which contracted 50 basis points (bps) year over year. Insurance medical care ratios (MCR) was 78% in the third quarter of 2024, which also contracted 50 bps year over year.
Clover Health’s Insurance members were 81,110 as of Sept. 30, 2024, down 0.2% year over year.
Other income generated revenues of $8.4 million in the third quarter, implying an improvement of 75.2% year over year.
Clover Health Investments, Corp. Price, Consensus and EPS Surprise
In the quarter under review, Clover Health’s net medical claims incurred increased 5.9% year over year to $249.8 million. Salaries and benefits expenses decreased 9.2% year over year to $54.9 million, while general and administrative expenses declined 14.2% year over year to $35.2 million. Total adjusted operating expenses of $339.9 million increased 0.8% on a year-over-year basis.
Total adjusted operating loss in the third quarter was $8.9 million compared with the prior-year quarter’s adjusted operating loss of $31.4 million.
Clover Health’s Financial Position
Clover Health exited third-quarter 2024 with cash and cash equivalents and short-term investments of $289.7 million compared with $264.4 million at the end of the second quarter.
Cumulative net cash provided by operating activities from continuing operations at the end of third-quarter 2024 was $129.5 million compared with $79.4 million a year ago.
CLOV’s Guidance
Clover Health has revised its outlook for 2024.
For 2024, Insurance revenues are continued to be estimated in the range of $1.35 billion-$1.375 billion.
For 2024, Insurance MCR is now expected to be in the range of 76-77%, lowered from the previous outlook of 77-79%. Insurance BER is now expected to be in the range of 81-82%, narrowed from the previous outlook of 81-83%.
Our Take
Clover Health exited the third quarter of 2024 with a narrower-than-expected loss per share. The uptick in consolidated revenues and both segments’ revenues was encouraging. The contraction in the Insurance BER and MCR was promising as well.
On the flip side, lower-than-expected revenues and continued dismal bottom-line performance was disappointing. CLOV incurred adjusted operating loss during the quarter, which did not bode well either.
Clover Health’s Zacks Rank & Key Picks
CLOV currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated (DGX - Free Report) , ResMed Inc. (RMD - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Quest Diagnostics, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2024 adjusted earnings per share (EPS) of $2.30, beating the Zacks Consensus Estimate by 1.8%. Revenues of $2.49 billion outpaced the consensus mark by 3.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has a long-term estimated growth rate of 6.5%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.4%.
ResMed reported first-quarter fiscal 2025 adjusted EPS of $2.20, beating the Zacks Consensus Estimate by 8.4%. Revenues of $1.22 billion surpassed the Zacks Consensus Estimate by 2.9%. It currently carries a Zacks Rank #2.
ResMed has a long-term estimated growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.4%.
Boston Scientific reported third-quarter 2024 adjusted EPS of 63 cents, beating the Zacks Consensus Estimate by 8.6%. Revenues of $4.21 billion surpassed the Zacks Consensus Estimate by 4.4%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
Clover Health Investments, Corp. (CLOV - Free Report) delivered a loss per share of 2 cents in the third quarter of 2024, narrower than the year-ago period’s loss of 7 cents per share and the Zacks Consensus Estimate of a loss of 3 cents per share.
CLOV’s Revenues in Detail
Clover Health registered revenues of $330.9 million in the third quarter, up 8.2% year over year. However, the figure missed the Zacks Consensus Estimate by 4.8%.
The top line was aided by robust Insurance revenues and Other income.
Shares of this company plunged nearly 12.7% in yesterday’s after-hours trading.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Clover Health’s Segmental Details
Clover Health derives its revenues from two business sources — Insurance and Other income.
Insurance revenues in the third quarter totaled $322.6 million, indicating an uptick of 7.1% year over year. Per management, this was primarily driven by strong member retention and continued intra-year growth.
Within CLOV’s Insurance segment, the Insurance Benefits Expense Ratio (BER) was 82.8% in the third quarter of 2024, which contracted 50 basis points (bps) year over year. Insurance medical care ratios (MCR) was 78% in the third quarter of 2024, which also contracted 50 bps year over year.
Clover Health’s Insurance members were 81,110 as of Sept. 30, 2024, down 0.2% year over year.
Other income generated revenues of $8.4 million in the third quarter, implying an improvement of 75.2% year over year.
Clover Health Investments, Corp. Price, Consensus and EPS Surprise
Clover Health Investments, Corp. price-consensus-eps-surprise-chart | Clover Health Investments, Corp. Quote
CLOV’s Operational Update
In the quarter under review, Clover Health’s net medical claims incurred increased 5.9% year over year to $249.8 million. Salaries and benefits expenses decreased 9.2% year over year to $54.9 million, while general and administrative expenses declined 14.2% year over year to $35.2 million. Total adjusted operating expenses of $339.9 million increased 0.8% on a year-over-year basis.
Total adjusted operating loss in the third quarter was $8.9 million compared with the prior-year quarter’s adjusted operating loss of $31.4 million.
Clover Health’s Financial Position
Clover Health exited third-quarter 2024 with cash and cash equivalents and short-term investments of $289.7 million compared with $264.4 million at the end of the second quarter.
Cumulative net cash provided by operating activities from continuing operations at the end of third-quarter 2024 was $129.5 million compared with $79.4 million a year ago.
CLOV’s Guidance
Clover Health has revised its outlook for 2024.
For 2024, Insurance revenues are continued to be estimated in the range of $1.35 billion-$1.375 billion.
For 2024, Insurance MCR is now expected to be in the range of 76-77%, lowered from the previous outlook of 77-79%. Insurance BER is now expected to be in the range of 81-82%, narrowed from the previous outlook of 81-83%.
Our Take
Clover Health exited the third quarter of 2024 with a narrower-than-expected loss per share. The uptick in consolidated revenues and both segments’ revenues was encouraging. The contraction in the Insurance BER and MCR was promising as well.
On the flip side, lower-than-expected revenues and continued dismal bottom-line performance was disappointing. CLOV incurred adjusted operating loss during the quarter, which did not bode well either.
Clover Health’s Zacks Rank & Key Picks
CLOV currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated (DGX - Free Report) , ResMed Inc. (RMD - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Quest Diagnostics, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2024 adjusted earnings per share (EPS) of $2.30, beating the Zacks Consensus Estimate by 1.8%. Revenues of $2.49 billion outpaced the consensus mark by 3.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has a long-term estimated growth rate of 6.5%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.4%.
ResMed reported first-quarter fiscal 2025 adjusted EPS of $2.20, beating the Zacks Consensus Estimate by 8.4%. Revenues of $1.22 billion surpassed the Zacks Consensus Estimate by 2.9%. It currently carries a Zacks Rank #2.
ResMed has a long-term estimated growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.4%.
Boston Scientific reported third-quarter 2024 adjusted EPS of 63 cents, beating the Zacks Consensus Estimate by 8.6%. Revenues of $4.21 billion surpassed the Zacks Consensus Estimate by 4.4%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.